popular wires

Want to know who is buying and selling their own stock? Join Livewire's Chris Conway and Kerry Sun for our quarterly update.

Historically, a small but significant percentage of active managers have outperformed the reference asset class category benchmark each year. According to S&P’s ‘SPIVA...

Rising unemployment has almost reached the "Sahm rule" threshold that has historically been a useful guide to US recessions.

A surprisingly great year for global shares despite significant inflation, interest rates and political risks.

Get up to date on overnight market activity and the big events for the day.

Elston Asset Management co-founder and PM, Bruce Williams, shares insights from his near 30 years in markets in this Views From the Top.

Assets acquired from collapsed German fintech giant Wirecard have taken time to bed down but are now delivering substantial rewards.

The June CPI reading puts the Federal Reserve (Fed) on the path to a September rate cut. Not only is this the second consecutive weaker-than-expected reading, but June...

T. Rowe Price's Sam Ruiz and Wilson Asset Management's Oscar Oberg are glass half full - here, they explain why.

As contrarian investors, we tend to shy away from popular and exciting stocks. By investing in companies that are out of favour, and therefore showing potential for...

In a paltry year for global bond investments, these funds stood out.

Aussie property has hit record highs, leaving prospective owners and investors wondering what comes next.

Former geologist James Cooper looks at the emerging opportunity in the High-Purity Alumina market. This is a true future-facing mineral.

If you’re bullish on gold, should you buy ASX gold stocks? Research suggests this isn’t always the best way to go. Just buy gold instead.

There is good reason to expect the $A to rise into next year, and a strong case for a slight weighting toward hedged global investments

There is no obvious plan to end the Russia-Ukraine war, but plenty of active plans to prolong it.

There were three companies in the Pharma & Biotech sector whose share prices rallied 70%+ in June, although share price increases for the sector were relatively muted...

It’s been a stellar year for global equities, courtesy of the tech-fuelled boom, but which fund managers topped the charts?

Plus, the key factors investors should be aware of when investing in tech companies over the coming year.

One or more brokers lifted their ratings for these companies during June.